# US 2012/0232060 A1 · Modified release preparations containing oxcarbazepine and derivatives thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0232060 A1
- Document ID: US20120232060A1
- Status: Published application
- Kind: A1
- Application number: 13/476,337
- Filed: 2012-05-21
- Published: 2012-09-13
- Earliest claimed: 2006-04-26
- Assignees: Supernus Pharmaceuticals, Inc.
- Inventors: Padmanabh P. Bhatt; Argaw Kidane; Kevin Edwards
- Web page: https://patentgrep.com/patent/US20120232060A1

## CPC

- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 9/0073: {Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; (nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M)}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/2031: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers}
- A61K 9/205: {Polysaccharides, e.g. alginate, gums; Cyclodextrin}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61K 2800/56: Compounds, absorbed onto or entrapped into a solid carrier, e.g. encapsulated perfumes, inclusion compounds, sustained release forms
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.

## Claims

### Claim 1

A pharmaceutical formulation for once-a-day administration of oxcarbazepine comprising: (a) oxcarbazepine; (b) at least one agent that enhances the solubility of oxcarbazepine; (c) at least one release promoting agent comprising a polymer having pH-dependent solubility, and (d) a carrier matrix comprising a water-swellable polymer, wherein components (a)-(c) are distributed in the carrier matrix.

### Claim 2 (depends on 1)

The formulation of claim 1, wherein the agent that enhances the solubility of oxcarbazepine is selected from the group consisting of surface active agents, complexing agents, cyclodextrins, pH modifying agents, and hydration promoting agents.

### Claim 3 (depends on 2)

The formulation of claim 2, wherein the surface active agents comprise sodium docusate, sodium lauryl sulfate, sodium stearyl fumarate, polyethylene oxide (PEO) modified sorbitan monoesters, fatty acid sorbitan esters, polyethylene oxide-polypropylene oxide-(poly(ethylene oxide)) block copolymers, or combinations thereof.

### Claim 4 (depends on 1)

The formulation of claim 1, wherein the water-swellable polymer is selected from the group consisting of cellulosic polymers, alginates, gums, cross-linked polyacrylic acid, carageenan, polyvinyl pyrrolidone, polyethylene oxides, and polyvinyl alcohol.

### Claim 5 (depends on 4)

The formulation of claim 4, wherein the cellulosic polymers are selected from the group consisting of hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC), hydroxyethylcellulose (HEC), methylcellulose (MC), powdered cellulose, cellulose acetate, sodium carboxymethylcellulose, calcium salt of carboxymethylcellulose, and ethylcellulose.

### Claim 6 (depends on 1)

The formulation of claim 1, wherein the release-promoting agent is selected from the group consisting of cellulose acetate phthalate, cellulose acetate succinate, methylcellulose phthalate, ethylhydroxycellulose phthalate, polyvinylacetate phthalate, polyvinylbutyrate acetate, vinyl acetate-maleic anhydride copolymer, styrene-maleic mono-ester copolymer, and Eudragit L100-55 (Methacrylic Acid-Ethyl Acrylate Copolymer (1:1)), and methyl acrylate-methacrylic acid copolymers.

### Claim 7 (depends on 1)

The pharmaceutical formulation of claim 1, wherein total amount of the release promoting agent and the agent that enhances the solubility of oxcarbazepine is up to 90% by weight of the formulation.

### Claim 8 (depends on 7)

The pharmaceutical formulation of claim 7, wherein the agent that enhances the solubility of oxcarbazepine is incorporated in an amount from 1% to 80% by weight of the formulation.

### Claim 9 (depends on 1)

The pharmaceutical formulation of claim 1, wherein the amount of oxcarbazepine is effective to produce a steady state blood level of monohydroxy derivative of oxcarbazepine in the range of about 2 μg/ml to about 10 μg/ml.

### Claim 10 (depends on 1)

The pharmaceutical formulation of claim 1, wherein the formulation is effective in minimizing fluctuations between Cmin and Cmax of monohydroxy derivative of oxcarbazepine.

### Claim 11 (depends on 10)

The pharmaceutical formulation of claim 10, which provides Cmax levels of monohydroxy derivative of oxcarbazepine in the range of about 6 μg/ml to about 10 μg/ml and Cmin levels of monohydroxy derivative of oxcarbazepine in the range of about 2 μg/ml to about 5 μg/ml.

### Claim 12 (depends on 1)

The formulation of claim 1, wherein the amount of oxcarbazepine is 600 mg.

### Claim 13 (depends on 1)

The pharmaceutical formulation of claim 1 in the form of pellets, tablets, granules or capsules.

### Claim 14 (depends on 13)

The formulation of claim 13 in the form of tablets.

### Claim 15 (depends on 14)

The formulation of claim 14, wherein each tablet comprises 600 mg of oxcarbazepine.

### Claim 16 (depends on 1)

The formulation of claim 1, wherein the water-swellable polymer is present in the amount of from 1% to 50% by weight of the formulation.

### Claim 17 (depends on 1)

The formulation of claim 1, further comprising a lubricant selected from the group consisting of magnesium stearate, calcium stearate, zinc stearate, stearic acid, polyethylene glycol, leucine, glyceryl behenate, sodium stearyl fumarate, hydrogenated vegetable oils, and waxes.

### Claim 18 (depends on 17)

The formulation of claim 17, wherein the wax is selected from the group consisting of beeswax, camuba wax, cetyl alcohol, glyceryl stearate, glyceryl palmitate, and stearyl alcohol.

### Claim 19 (depends on 17)

The formulation of claim 17, wherein the lubricant is incorporated in the amount of from 0.1% to 20% by weight of the formulation.

### Claim 20 (depends on 1)

The pharmaceutical formulation of claim 1, wherein the polymer having pH-dependent solubility remains intact at pH values of below 4 and dissolves at pH values of more than 4.

### Claim 21 (depends on 1)

The pharmaceutical formulation of claim 1, wherein the polymer having pH-dependent solubility dissolves at pH values of more than 5.

### Claim 22 (depends on 1)

The pharmaceutical formulation of claim 1, wherein the polymer having pH-dependent solubility dissolves at pH values of more than 6.

### Claim 23 (depends on 1)

The formulation of claim 1, further comprising a tabletting aid selected from the group consisting of magnesium stearate, talc, cabosil, and silicified microcrystalline cellulose.

### Claim 24 (depends on 23)

The formulation of claim 23, wherein the tabletting aid is incorporated in the amount of up to 25% by weight of the formulation.

### Claim 25 (depends on 14)

The formulation of claim 14, wherein each tablet comprises a homogeneous admixture of oxcarbazepine with HPMC and methacrylic acid-ethyl acrylate copolymer.

### Claim 26 (depends on 6)

The formulation of claim 6, further comprising a surfactant and a tabletting aid.
